QuantumBio Appoints Lance Westerhoff, PhD as New CEO

[State College, PA, April 17, 2024] QuantumBio, a pioneering leader in computational chemistry software, proudly announces the appointment of Dr. Lance Westerhoff, PhD, as its new Chief Executive Officer (CEO), effective March 1, 2024. Dr. Westerhoff succeeds Dr. Walter Lovenburg, who retired from the position of Acting CEO in early 2024 after serving in this capacity for more than 20 years. The transition in leadership marks a pivotal moment for QuantumBio as it expands its technological and scientific innovation efforts in order to continue to provide cutting-edge software modeling tools and services for the pharmaceutical industry.

Dr. Lovenburg‘s tenure as Acting CEO has been marked by his distinguished background as a high-level executive in biopharma, with significant contributions to renowned organizations such as OSI Pharmaceuticals, Merrimack Pharmaceuticals, and the National Institutes of Health, where he served as Chief of the Section of Biochemical Pharmacology. The Board of Directors extends its deepest gratitude to Dr. Lovenburg for his more than two decades of dedicated service and eagerly anticipates his ongoing contributions as a valued member of the board.

Dr. Lovenburg expressed his confidence in Dr. Westerhoff’s abilities and his excitement for the company’s future. “I am proud to have been a part of QuantumBio’s journey and I have full faith in Dr. Westerhoff’s leadership. I look forward to continuing to support the company as a member of the Board,” he said.

In assuming the role of CEO, Dr. Lance Westerhoff brings a wealth of expertise and experience to QuantumBio. Dr. Westerhoff is not only an accomplished entrepreneur but also a seasoned computational biochemist who has served as General Manager and President of the company for more than 15 years, making him intimately familiar with QuantumBio’s operations, goals, and values. His multifaceted skill set encompasses project management, software engineering, strategic planning, and fundraising. In particular, he has served as the Principal Investigator and Co-Principal Investigator on numerous SBIR/STTR grants over his tenure at QuantumBio.

A published scientist with a focus on the synergistic application of quantum mechanics and molecular mechanics in the life and pharmaceutical sciences, Dr. Westerhoff has played a pivotal role in driving QuantumBio’s research, development, and deployment of advanced solutions in linear scaling QM/MM characterization, fast free energy methods, and cutting edge X-ray/Cryo-EM techniques. His leadership has been instrumental in successfully marketing QuantumBio’s innovative tools to the pharmaceutical industry, establishing the company as a trailblazer in computational biochemistry.

“We are thrilled to welcome Dr. Lance Westerhoff as QuantumBio’s new CEO,” said Walter Greenblatt, Director of the Board at QuantumBio. “His exceptional leadership qualities, coupled with his deep understanding of both the scientific and business aspects of our industry, make him the ideal candidate to lead QuantumBio into its next phase of growth and innovation. We are confident that under Dr. Westerhoff’s stewardship, QuantumBio will continue to revolutionize computer aided drug design and structural biology and drive meaningful impact in the pharmaceutical landscape.”

Dr. Lance Westerhoff expressed his enthusiasm for his new role, stating, “I am honored to lead QuantumBio as we embark on the next chapter of our journey. QuantumBio’s pioneering work at the intersection of quantum mechanics and molecular mechanics has the potential to revolutionize drug discovery and development. Building on the foundation laid by Dr. Lovenburg and our talented team, I am committed to further advancing our mission of innovative and impactful solutions that drive transformative scientific discoveries which ultimately benefit patients worldwide.”

The entire QuantumBio team extends its heartfelt gratitude to Dr. Lovenburg for his years of dedicated service and warmly welcomes Dr. Westerhoff as he assumes his new responsibilities as CEO.

The appointment of Dr. Westerhoff as the new CEO of QuantumBio marks an exciting new chapter for the company. With his leadership and the support of the Board, QuantumBio is poised for continued success in the pharmaceutical industry.

For media inquiries please contact:

Lance Westerhoff


QuantumBio offers a powerful suite of innovative software products purpose-built for life sciences on cutting-edge science that utilizes the highest levels of theory available to achieve peak accuracy, performance, and versatility. Through our science-first, customer-centric approach, we make precision quantum mechanical approaches more user-friendly, cost-effective and easily accessible. We help pharmaceutical, biotech, and academic scientists improve their understanding of biochemical structure and function while enhancing the drug discovery process.